Preformulation of a liquid dosage formulation of captopril for pediatric use: drug-excipient compatibility and stability studies
AUTOR(ES)
Goes, Janaina da Silva
FONTE
Braz. J. Pharm. Sci.
DATA DE PUBLICAÇÃO
20/12/2019
RESUMO
Currently, medications used in children are typically modified from pharmaceutical dosage forms designed for adults. Captopril is widely adapted to liquid formulations for use in hospitals. Its stability in the aqueous medium is reduced since it undergoes oxidation producing captopril disulfide (its main metabolite). The aim of this formulation study was to suggest favorable conditions for the development of a stable captopril formulation. The compatibility between the drug and excipients was evaluated by differential scanning calorimetry analysis (DSC). For studies in solution, different formulations were prepared according to a factorial design varying EDTA concentration, water purity and pH. The resultant formulations were stored at 60°C and analyzed over a twelve-day period using HPLC. The DSC curves obtained suggested, although not conclusive to elucidation, interactions of captopril with citric acid and sucralose. The stability study of these solutions revealed that the variables significantly influenced captopril content, which degraded at zero order kinetics and rates differing by a factor of up to 7 times, where pH proved the most influential factor. Interactions between variables were observed. Therefore, development of a stable captopril formulation is feasible provided EDTA and a buffering agent is used at suitable concentrations (0.08% and pH 3.85).
Documentos Relacionados
- Assessing Drug-Excipient Interactions in the Formulation of Isoniazid Tablets
- Estudo termoanalítico e de compatibilidade fármaco-excipiente de rifampicina e alguns medicamentos utilizados na terapêutica da tuberculose
- The solution and solid state stability and excipient compatibility of parthenolide in feverfew
- Compatibility drug/excipient and stability studies of prednicarbate by thermal analysis, and loading of drug in mesoporous silica type SBA-15
- Compatibility and stability of valsartan in a solid pharmaceutical formulation